Because BCL-2 and BCL-xL inhibitors fail to target MCL-1, MCL-1 expression is an obvious potential mechanism by which cancer cells resist treatment with ABT-263, and this mechanism has been demonstrated in some cancer models [35, 36]. Here, BCL2L1 is linked to cancer.